Additionally, we provide space in our office for ChinaSF, a collaborative public/private economic development initiative that is operated by the San Francisco Center for Economic Development and the City of San Francisco, with the financial and strategic backing of key international business leaders. ChinaSF works to foster trade and economic development between San Francisco and China.
NOTE: Nixon Peabody LLP is a limited liability partnership organized and registered under the laws of the State of New York. A list of the names of the partners and their professional qualifications is open to inspection at any of its offices. Lawyers in our Shanghai office are not licensed as local lawyers in the People’s Republic of China.
San Francisco Business Times | April 28, 2022
This article covers a recent “Bridge from China” event, sponsored by NP, that included discussion of how the pandemic has affected cross-border business, and how to potentially tackle complex nuances of U.S.-China political and business relationships. David Cheng, chair and managing partner of NP’s China & Asia Pacific practice, served as a panelist, and David Kaufman, director of Global Strategies, co-moderated the panel discussion.
The American Lawyer | November 22, 2021
This article on the surge in private equity deals includes NP for advising the owners of skin care brand Obagi in its $1.2 billion business combination agreement with Waldencast Acquisition Corp. and the spinoff of Obagi’s operations in China.
The NP team was led by David Cheng, chair and managing partner of the firm's China and Asia-Pacific practice, and New York City Corporate partners Michael Smith and Richard Langan. The team that advised Obagi also included Chicago Corporate partner David Brown, Rochester Corporate partner Jeremy Wolk, Washington, DC Complex Commercial Disputes partner and Antitrust team leader Gordon Lang, and Washington, DC Corporate senior counsel Kenneth Silverberg. Other members of the team included Boston Corporate associate Anthony Bova and Chinese legal consultant Kelly Xiang.
Bloomberg Law | November 18, 2021
This article covering a roughly $1.2 billion merger of skin care and beauty brands with a special purpose acquisition company mentions NP for advising the owners of skin care brand Obagi in its business combination agreement with Waldencast Acquisition Corp. and the spinoff of Obagi's operations in China.
The NP team was led by David Cheng, chair and managing partner of the firm's China and Asia-Pacific practice, and New York City Corporate partners Michael Smith and Richard Langan. The team that advised Obagi also included Chicago Corporate partner David Brown, Rochester Corporate partner Jeremy Wolk, Washington, DC Complex Commercial Disputes partner and Antitrust team leader Gordon Lang, and Washington, DC Corporate senior counsel Kenneth Silverberg. Other members of the team included Boston Corporate associate Anthony Bova and Chinese legal consultant Kelly Xiang.
San Francisco Business Times | February 26, 2021
This article covers a recent “Bridge from China“ event, sponsored by NP, that included discussion of how the pandemic has affected cross-border business, geopolitical tensions of recent years, and what the administration change could mean for U.S. businesses wanting to do business in China. David Cheng, chair and managing partner of NP’s China & Asia Pacific practice, served as a panelist and David Kaufman, director of Global Strategies, co-moderated the panel discussion.
1350 North Sichuan Road
Shanghai 200080
China
Phone: +86 21 6137 5500
Fax: +86 21 6137 5588
